 <h1>Icosapent Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to icosapent: oral capsule liquid filled</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, icosapent may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking icosapent:</p><p>
<i>Less common</i>
</p><ul>
<li>Dizziness</li>
<li>fainting</li>
<li>fast or irregular heartbeat</li>
<li>lightheadedness</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>unusual bleeding</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of icosapent may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>difficulty with moving</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>pain in the mouth or throat</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Diarrhea</li>
<li>pain in the arms or legs</li>
<li>stomach discomfort</li>
</ul><p>
<!-- end oral capsule liquid filled --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to icosapent: oral capsule</i></p><h3>General</h3><p>The more commonly reported adverse reactions in the cardiovascular outcome trial included musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation.  The more commonly reported adverse reactions in the hypertriglyceridemia trials included arthralgia and oropharyngeal pain.</p><h3>Cardiovascular</h3><p>During clinical trials in patients with established cardiovascular disease (CVD) or diabetes plus and additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 hours or more occurred in 3% of patients (n=127) receiving this drug compared with 2% (n=84) placebo-treated patients.  The incidence of atrial fibrillation was greater in patients with a history of atrial fibrillation or atrial flutter.</p><p><b>Common</b> (1% to 10%): Atrial fibrillation/flutter, peripheral edema</p><h3>Hematologic</h3><p>During clinical trials in patients with established cardiovascular disease (CVD) or diabetes plus and additional risk factor for CVD, a bleeding event occurred in 12% (n=482) of patients receiving this drug compared to 10% (n=404) of placebo-treated patients.  A serious bleeding event occurred in 3% (n=111) of patients receiving this drug compared to 2% (n=85) of placebo-treated patients.</p>
<p></p>
<p>Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time.  The prolongation of bleeding time reported in those studies did not exceed normal limits and did not produce clinically significant bleeding episodes.<sup>[Ref]</sup></p><p>Very Common (10% or greater): Bleeding event </p>
<p><b>Common</b> (1% to 10%): Serious bleeding event </p>
<p><b>Frequency not reported</b>: Prolonged bleeding time<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, oropharyngeal pain </p>
<p><b>Postmarketing reports</b>: Diarrhea, abdominal discomfort<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, musculoskeletal pain</p>
<p><b>Postmarketing reports</b>: Extremity pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Gout</p>
<p><b>Postmarketing reports</b>: Increased blood triglycerides</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Vascepa (icosapent)." Amarin Pharmaceuticals Inc, Warren, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Lovaza vs. Vascepa - what's the difference between them?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about icosapent</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>93 Reviews</li>
<li>Drug class: miscellaneous antihyperlipidemic agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Icosapent ethyl &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Vascepa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cardiovascular Risk Reduction</li>
<li>Hypertriglyceridemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to icosapent: oral capsule</i></p><h3>General</h3><p>The more commonly reported adverse reactions in the cardiovascular outcome trial included musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation.  The more commonly reported adverse reactions in the hypertriglyceridemia trials included arthralgia and oropharyngeal pain.</p><h3>Cardiovascular</h3><p>During clinical trials in patients with established cardiovascular disease (CVD) or diabetes plus and additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 hours or more occurred in 3% of patients (n=127) receiving this drug compared with 2% (n=84) placebo-treated patients.  The incidence of atrial fibrillation was greater in patients with a history of atrial fibrillation or atrial flutter.</p><p><b>Common</b> (1% to 10%): Atrial fibrillation/flutter, peripheral edema</p><h3>Hematologic</h3><p>During clinical trials in patients with established cardiovascular disease (CVD) or diabetes plus and additional risk factor for CVD, a bleeding event occurred in 12% (n=482) of patients receiving this drug compared to 10% (n=404) of placebo-treated patients.  A serious bleeding event occurred in 3% (n=111) of patients receiving this drug compared to 2% (n=85) of placebo-treated patients.</p><p></p><p>Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time.  The prolongation of bleeding time reported in those studies did not exceed normal limits and did not produce clinically significant bleeding episodes.<sup>[Ref]</sup></p><p>Very Common (10% or greater): Bleeding event </p><p><b>Common</b> (1% to 10%): Serious bleeding event </p><p><b>Frequency not reported</b>: Prolonged bleeding time<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, oropharyngeal pain </p><p><b>Postmarketing reports</b>: Diarrhea, abdominal discomfort<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, musculoskeletal pain</p><p><b>Postmarketing reports</b>: Extremity pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Gout</p><p><b>Postmarketing reports</b>: Increased blood triglycerides</p><p id="ref_1">1. "Product Information. Vascepa (icosapent)." Amarin Pharmaceuticals Inc, Warren, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Lovaza vs. Vascepa - what's the difference between them?</li>
</ul><h2>More about icosapent</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>93 Reviews</li>
<li>Drug class: miscellaneous antihyperlipidemic agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Icosapent ethyl &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cardiovascular Risk Reduction</li>
<li>Hypertriglyceridemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>